[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Sznajd
J
J
Malczewska-Malec
M
M
Idzior-Waluś
B
B
Jamska
B
B
Nowacki
G
G
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood*; D014631:Valerates / Q000627:therapeutic use*
D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D002784:Cholesterol; D015248:Gemfibrozil
Ocena skuteczności Gemfibrozilu w pierwotnych dyslipoproteinemiach. Cześć I: Zmiany stezenia lipidów pod wpływem leczenia (redukcja "netto").